Brokerages Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.25

PolyPid Ltd. (NASDAQ:PYPD) has earned an average recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $11.80.

Several brokerages have recently weighed in on PYPD. JMP Securities dropped their price objective on shares of PolyPid from $16.00 to $14.00 and set a “market outperform” rating on the stock in a report on Tuesday. Roth Capital set a $9.00 target price on PolyPid and gave the company a “buy” rating in a research report on Wednesday. Finally, HC Wainwright upped their price target on PolyPid from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, June 9th.

PolyPid Price Performance

PolyPid stock opened at $3.31 on Tuesday. The stock has a market capitalization of $33.73 million, a price-to-earnings ratio of -0.77 and a beta of 1.25. PolyPid has a 52-week low of $2.30 and a 52-week high of $4.49. The company has a debt-to-equity ratio of 4.43, a quick ratio of 0.71 and a current ratio of 0.71. The stock’s 50 day moving average price is $2.90 and its two-hundred day moving average price is $2.92.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.10. On average, equities analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PYPD. Rosalind Advisors Inc. raised its stake in shares of PolyPid by 50.6% in the fourth quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after purchasing an additional 343,353 shares during the last quarter. AIGH Capital Management LLC boosted its position in shares of PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after buying an additional 148,199 shares during the last quarter. Finally, J. Goldman & Co LP bought a new stake in PolyPid during the fourth quarter worth $391,000. 26.47% of the stock is owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.